Business Wire

OR-ADVA

Share
PGE selects ADVA’s assured PNT solution for critical smart grid infrastructure

ADVA (FSE: ADV) today announced that Portland General Electric (PGE) is deploying Oscilloquartz PTP grandmaster clock technology as it upgrades to packet-based synchronization and protects its network against GNSS vulnerabilities and cyberattacks, while conforming to PNT Executive Order 13905. PGE, one of the largest power utilities in the Western United States, is using ADVA scalable timing solution to not only enable a smooth transition from legacy synchronization and ensure new levels of accuracy, reliability and resiliency but also to timestamp data and control grid substations at the edge. With multi-band GNSS receivers and AI-powered threat detection, ADVA’s assured PNT (aPNT) platform helps maintain resilient timing, even in challenging circumstances such as deliberate jamming and spoofing attacks. Easy to install and operate, the solution also provides multi-source backup, including PTP network timing and in-device holdover oscillators for when GNSS signals are unavailable or disrupted.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005033/en/

“Precise and resilient synchronization is increasingly vital in the power industry. By harnessing new time-sensitive applications and building smarter energy infrastructure, we can offer even more to customers across our region. ADVA’s Oscilloquartz technology will be a key tool as we continue to lead the way to a more sustainable and affordable energy future for our community,” said John Lozano, senior telecommunications engineer, PGE. “ADVA’s OSA 5420 Series supports our existing synchronization services while also enabling packet time distribution all the way to the edge of our network. With its GPS jamming and spoofing detection, it provides a robust yet cost-efficient defense against cyber threats. It also makes maintenance and configuration simple with an easy-to-operate web GUI and customizable database.”

PGE’s new timing infrastructure will distribute stable and accurate frequency, phase and time-of-day information between its power infrastructure data points, including PMUs, IEDs and substation LAN IEC 61850 communications, supporting rapid decision-making and automated assurance. The solution is built on the OSA 5410 and OSA 5420 Series of edgeSync+™ grandmaster clocks. It features multi-band, multi-constellation GNSS receivers and supports multiple PTP profiles, including substation power and core telecom backup sync, while also allowing conversion between them and supporting legacy interfaces. The products are part of ADVA’s new aPNT platform, integrating threat detection, multi-source backup and ADVA’s intelligent Ensemble Sync Director , as the new trusted standard for PNT service assurance, control and visibility.

“We’re proud that PGE is leveraging our synchronization technology and the support of our team as it makes the shift to next-generation timing. With its compact and environmentally friendly design, our technology will bring assured and protected synchronization to the edge of PGE’s network, enhancing efficiency and enabling it to take advantage of emerging smart grid applications,” commented John Scherzinger, SVP, sales, Americas, ADVA. “PGE’s highly resilient new solution will deliver the nanosecond accuracy and the levels of timing availability required by tomorrow’s power utilities. It features aPNT capabilities, our centralized GNSS monitoring and assurance tool for predictive maintenance, and our multi-band receivers with the power to compensate for ionospheric delay variations and protect against GNSS vulnerabilities.”

Further information on ADVA’s aPNT platform is available in this sync guide: https://adva.li/apnt-sync-guide .


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye